Compare FMC Corp (FMC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Sanofi SA — how do they compare? FMC Corp trades at $10.48 (market cap $1.31B), while Sanofi SA trades at $43.25 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 79.8× FMC Corp's market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.
| FMC | SNY | |
|---|---|---|
Market Cap | $1.31B | $104.57B |
Sector | Basic Materials | Health |
52-Week High | $40.69 | $52.34 |
52-Week Low | $10.01 | $41.33 |
Enterprise Value | $5.11B | $124.48B |
Dividend Yield | 3.06% | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $10.59, up 0.38% today, with a bearish technical signal from moving averages. The stock shows mixed earnings beats but faces severe profitability challenges, with a net income margin of -84.83% and negative ROE of -91.47% for 2025. Recent news highlights revenue declines and cost management efforts, including a $400 million investment from Tessenderlo Group to reduce debt.
The outlook remains cautious due to persistent losses and competitive pressures in agricultural sciences. Upside exists if operational improvements and debt reduction stabilize finances, but high volatility and margin pressures pose significant risks to shareholder value.
SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.
SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
